Cristina Andreu Vázquez-rekin lankidetzan egindako argitalpenak (3)

2022

  1. Early predictive risk factors for dimethyl fumarate-associated lymphopenia in patients with multiple sclerosis

    Multiple Sclerosis and Related Disorders, Vol. 59

2020

  1. Three-Year Effectiveness of Dimethyl Fumarate in Multiple Sclerosis: A Prospective Multicenter Real-World Study

    CNS Drugs, Vol. 34, Núm. 12, pp. 1275-1286

  2. Tolerability and safety of dimethyl fumarate in relapsing multiple sclerosis: a prospective observational multicenter study in a real-life Spanish population

    Journal of Neurology, Vol. 267, Núm. 8, pp. 2362-2371